Originally established in 2000 as the Italian site of Merck & Co’s Research Laboratories and becoming independent in 2010, IRBM stands as a powerful force in drug discovery. With a focus on cancer, neurological disorders, infection, and rare diseases, our contributions include four approved therapeutics and over 25 candidates currently in clinical trials. Our comprehensive expertise encompasses peptides, small molecules, and antibody therapeutics, guided by a seasoned leadership team that brings high-level R&D insight to your project.
Operating from state-of-the-art facilities, we provide integrated solutions and swift project execution, all under one roof to ensure rapid transitions, strategic decision making, and expedited outcomes. Your program will be supported by a team of highly adaptable scientists and a dedicated project representative, offering customized solutions based on your evolving needs.